(Bloomberg) -- Edesa Biotech Inc. shares tripled after the U.S. Food and Drug Administration said the company could proceed with its clinical study of a potential new treatment for dermatitis.
ADVERTISEMENT
The stock jumped a record 220% on Thursday to its highest level since May 31. The company’s market is now about $73 million. Edesa expects to enroll the first patient in the mid-stage trial of its drug, EB01, in the coming quarter.
ADVERTISEMENT
©2019 Bloomberg L.P.
RECOMMENDED FOR YOU
POPULAR
1
M&M Financial Q4 Results: Profit Falls 9.5%, Misses Estimates
2
Mahindra Finance Fraud At Mizoram Branch Impacted Q4 Profit By Rs 135.86 Crore
3
Buffett Says US Corporate Taxes Likely To Rise To Tame Deficit
4
AI Scamming To Emerge As Next 'Growth Industry', Says Warren Buffett
5